European submission for COVID-19 vaccination in children

30 April 2021

The first coronavirus vaccine for children could soon be available in Europe, after Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) submitted to broaden the Conditional Marketing Authorization for their Comirnaty jab.

The regulatory bid comes several weeks after the firms submitted to the US Food and Drug Administration to broaden the Emergency Use Authorization (EUA) in the same way.

If approved, the firms will be able to offer the coronavirus vaccine for children aged 12 to 15, with Phase III data showing the therapy is safe and effective for this age group.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK